Showing results (141-150 of 160) with videos related to

Sort By:
Pageof 16
Antimicrobial Agents and Chemotherapy|July 25, 2018
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B InfectionAndrea L Cathcart, Henry Lik-Yuen Chan, Neeru Bhardwaj, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 9, 2024
Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48Tarik Asselah, Pietro Lampertico, Soo Aleman, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|July 31, 2025
Switching to tenofovir alafenamide in virally-suppressed chronic hepatitis B patients with renal/hepatic impairment: Phase 2 study sub-analysis from TaiwanChun-Jen Liu, Young-Suk Lim, Chi-Yi Chen, et al.
Journal of Clinical and Translational Hepatology|July 5, 2021
3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in ChinaJinlin Hou, Qin Ning, Zhongping Duan, et al.
The Journal of Trauma|April 11, 2008
Joint Theater Trauma System implementation of burn resuscitation guidelines improves outcomes in severely burned military casualtiesJody L Ennis, Kevin K Chung, Evan M Renz, et al.
Journal of Hepatology|August 23, 2016
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised studyScott Fung, Peter Kwan, Milotka Fabri, et al.
The Lancet. Gastroenterology & Hepatology|June 20, 2024
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 studyHarry L A Janssen, Young-Suk Lim, Pietro Lampertico, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeksScott K Fung, Calvin Q Pan, Grace Lai-Hung Wong, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialMaria Buti, Edward Gane, Wai Kay Seto, et al.
The American Journal of Gastroenterology|August 10, 2023
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone SafetyHenry L Y Chan, Maria Buti, Young-Suk Lim, et al.
Pageof 16